Osteoporosis: Causes, Symptoms, Diagnosis, Fracture Risk, and Treatment (Complete Guide)

Osteoporosis is one of the most consequential and underdiagnosed chronic diseases of the modern era. It produces no pain, no visible symptoms, and no warning signs in its early stages. People can live with significant bone loss for years without knowing it. The first sign for many patients is a fracture, often after a fall that would not have injured someone with healthy bones, and sometimes after no clear injury at all.

The disease is often referred to as the silent thief of bone, and the description fits. Bone is removed gradually from the skeleton, year after year, with no sensation that anything is changing. Only when a vertebra collapses, a hip breaks during a routine fall, or a wrist fractures during a minor stumble does the underlying disease become visible. By that point, treatment options are still meaningful, but the opportunity to prevent the fracture in the first place has passed.

Yet the prognosis after a major osteoporotic fracture, particularly a hip fracture in an older adult, is sobering. Mortality in the year following a hip fracture can reach 20 to 30 percent in older populations. Many survivors lose their independence permanently. Vertebral fractures, often invisible on the day they occur, accumulate silently and gradually deform the spine, reduce height, and impair quality of life across decades.

This is what makes osteoporosis worth understanding. The disease is preventable, treatable, and detectable long before the consequences appear. With appropriate screening, lifestyle intervention, and modern medication when indicated, most fractures can be avoided entirely. The challenge is that recognition often comes too late.

This guide explains how osteoporosis develops, who is at risk, how it is diagnosed, and how modern treatment is reshaping outcomes for the millions of people who live with the disease.

What Osteoporosis Is

Osteoporosis is a disease of the skeleton in which bones become weaker, thinner, and more porous, predisposing them to fracture. The name itself describes the underlying problem: porous bone. On microscopic examination, osteoporotic bone contains larger spaces and thinner connecting struts than healthy bone. The architecture that gives bone its strength is gradually eroded.

The condition is defined formally by a measurement of bone mineral density. When bone density is reduced by 2.5 standard deviations or more compared to the average peak density in young, healthy adults of the same sex, the diagnosis of osteoporosis is established. This formal threshold is captured in a measurement called the T-score, which is discussed in detail later in this guide.

Beyond the formal definition, osteoporosis is a clinical condition. Its consequences are fractures, and the most important fractures occur at the hip, the spine, and the wrist. Each carries its own pattern of impact on long-term health, but together they account for the great majority of the disease's burden on individuals and on healthcare systems.

How the Skeleton Normally Maintains Itself

Bone is not a static tissue. It is a dynamic, living structure that is continuously being broken down and rebuilt throughout life, in a process called bone remodeling. Two cell types drive this process. Osteoclasts dissolve old bone, removing it through the action of acids and enzymes. Osteoblasts then build new bone in the same location, depositing fresh collagen and minerals to replace what was removed.

In a healthy adult, this process is tightly balanced. The amount of bone removed equals the amount of bone laid down, and total bone mass remains stable. The remodeling cycle takes several months at any given site, and at any moment, a small percentage of the skeleton is undergoing active remodeling.

The balance depends on a complex network of hormones, nutrients, and mechanical signals. Estrogen, in women, is one of the most important regulators, suppressing osteoclast activity and helping maintain bone mass. Testosterone plays a similar role in men, though its effect is less dramatic. Vitamin D and calcium provide the raw materials and signaling necessary for bone formation. Mechanical loading, the stress placed on bones by gravity and physical activity, signals bones to maintain their strength.

Osteoporosis develops when this balance is disrupted. When bone resorption exceeds bone formation, even by a small amount, the deficit accumulates over time. Year after year, a little less bone is replaced than is removed. Over decades, the cumulative loss can be substantial, even though no single year produces a dramatic change.

Why Osteoporosis Develops

Several distinct pathways can lead to the imbalance that produces osteoporosis. In most patients, a combination of factors contributes.

Postmenopausal Bone Loss

In women, the most common cause of osteoporosis is the decline in estrogen that accompanies menopause. Estrogen is a powerful suppressor of bone resorption, and its withdrawal triggers a period of rapid bone loss. Women typically lose 2 to 3 percent of bone mass per year in the first several years after menopause, with rates gradually declining thereafter.

This pattern of postmenopausal bone loss is the reason osteoporosis is more common in women than in men, and it is why screening guidelines focus particularly on women in the years following menopause.

Age-Related Bone Loss

Beyond the specific effects of menopause, both men and women lose bone gradually with age. The reasons are not fully understood but include reduced osteoblast function, lower vitamin D synthesis in older skin, decreased calcium absorption from the gut, and changes in hormonal regulation. Age-related bone loss occurs in both sexes and accumulates across decades.

Secondary Osteoporosis

A meaningful proportion of osteoporosis cases are caused by underlying conditions or medications, a situation referred to as secondary osteoporosis. Common contributors include hyperthyroidism, diabetes, chronic kidney disease, liver disease, inflammatory bowel disease, celiac disease, rheumatoid arthritis, chronic lung disease, and certain hormonal conditions.

Several medications increase the risk of osteoporosis. Long-term use of corticosteroids, including prednisone, is one of the most important. Aromatase inhibitors, used in the treatment of hormone receptor-positive breast cancer, accelerate bone loss substantially. Certain anticonvulsants, proton pump inhibitors used long-term, and selected other medications have also been associated with reduced bone density.

For more on secondary causes, see Secondary Osteoporosis: Causes and When to Suspect It.

Lifestyle and Genetic Factors

Smoking, excess alcohol consumption, sedentary lifestyle, low body weight, and inadequate calcium and vitamin D intake all contribute to bone loss. Genetic factors play a meaningful role: family history of osteoporosis or hip fracture is one of the stronger individual risk predictors.

An interesting biological observation reinforces the role of mechanical loading in maintaining bone. Astronauts on extended space missions experience substantial bone loss in microgravity, sometimes losing 1 to 2 percent of bone density per month. The skeleton, in the absence of the mechanical stress provided by gravity and physical activity, gradually withdraws bone that is no longer being used. This phenomenon highlights why physical activity is so important to bone health and why prolonged immobility, in any context, accelerates bone loss.

For more on the broader risk factor picture, see What Causes Osteoporosis? Risk Factors Explained.

Why Osteoporosis Is Often Silent

One of the defining features of osteoporosis is that it produces no symptoms in its early and intermediate stages. Bone loss does not cause pain. There is no characteristic discomfort, no warning ache, no signal that something is wrong. The disease can progress for years or decades without alerting the person who has it.

Symptoms appear only when fractures occur. Even then, some fractures are subtle. Vertebral compression fractures, the most common type, are often painless or produce only mild back discomfort that is dismissed as routine aging. They can accumulate silently, gradually shortening the spine and producing a stooped posture, without the patient ever recognizing that fractures are taking place.

This silent progression has practical implications. Osteoporosis cannot be detected through symptom recognition alone. It must be screened for, particularly in populations at increased risk. The patients who would benefit most from early intervention, those whose disease is still progressing without consequences, often have no reason to seek evaluation.

For more on what to watch for, see Symptoms of Osteoporosis: Early Signs You Should Not Ignore.

The Differences Between Women and Men

Osteoporosis has historically been viewed as a disease of women, and women are indeed affected more commonly. The hormonal changes of menopause produce a distinct pattern of accelerated bone loss that has no direct equivalent in men.

But men are not immune. Osteoporosis and osteoporotic fractures are common in men as well, particularly at older ages. One in three men over the age of 50 will experience an osteoporotic fracture in their remaining lifetime, a rate higher than many people realize. Yet men are screened far less frequently than women, and osteoporosis in men is often diagnosed only after a fracture has occurred.

Why the difference? Multiple factors contribute. Bone loss in men is more gradual than in women and is not accelerated by a specific event like menopause. Testosterone plays a protective role for bone, and it declines more gradually with age than estrogen does. Additionally, cultural attitudes and screening guidelines have traditionally focused on women, leaving men with less awareness and less access to screening.

The net effect is that osteoporosis in men is frequently undiagnosed until a fracture brings it to light. Guidelines increasingly recommend screening men at age 70 or older, and earlier in men with risk factors, but implementation of this recommendation has lagged.

For more on this topic, see Osteoporosis in Women vs Men: Key Differences.

How Osteoporosis Is Diagnosed

Diagnosis of osteoporosis depends on measurement of bone mineral density, most commonly accomplished with a test called dual-energy x-ray absorptiometry, or DXA scan.

The DXA Scan

The DXA scan is a low-radiation x-ray technique that measures the density of bone at specific sites, typically the hip and the lumbar spine. The test is quick, painless, and involves minimal radiation exposure. It produces a numerical score called the T-score, which compares the patient's bone density to the average peak density of young, healthy adults.

A T-score of -1.0 or higher is considered normal. A T-score between -1.0 and -2.5 indicates osteopenia, a condition of reduced bone density that does not yet meet the criteria for osteoporosis but indicates elevated fracture risk. A T-score of -2.5 or lower establishes the diagnosis of osteoporosis.

The DXA scan also measures bone mineral density as an absolute number, usually expressed in grams of mineral per square centimeter. The change in this measurement over time is used to monitor response to treatment.

Who Should Be Screened

Screening recommendations are based on age, sex, and risk factors. Standard recommendations suggest DXA screening for all women age 65 and older, all men age 70 and older, and younger women and men with specific risk factors.

Risk factors that warrant earlier screening include family history of osteoporosis or hip fracture, personal history of prior fracture, corticosteroid use, other medications or conditions known to affect bone density, low body weight, smoking, and excessive alcohol use.

For more on screening, see Bone Density Test (DXA): What It Is and How to Read Results.

Additional Tests

Beyond the DXA scan, other tests can provide additional information. Blood tests can identify reversible causes of bone loss, including vitamin D deficiency, hyperthyroidism, and hyperparathyroidism. Tests of bone turnover markers can identify patients with particularly rapid bone loss and may help predict response to treatment.

When indicated, additional imaging or specialized tests may be performed to evaluate for secondary causes of osteoporosis or to assess fracture risk in greater detail.

Fracture Risk Assessment Beyond Bone Density

Bone mineral density is important, but it is not the complete picture of fracture risk. Many fractures occur in people with osteopenia rather than osteoporosis, and not all people with osteoporosis experience fractures.

Risk assessment tools that incorporate additional clinical factors can better predict fracture risk than bone density alone. The most widely used is the FRAX tool (Fracture Risk Assessment Tool), which uses clinical information including age, sex, body weight, smoking status, alcohol use, history of fractures, family history of hip fracture, and DXA T-score to estimate the 10-year probability of major osteoporotic fracture and hip fracture.

FRAX is useful in guiding treatment decisions, helping identify patients who might benefit from medication even if their bone density is not yet in the osteoporotic range, and in assessing the urgency of intervention.

For more on fracture risk, see T-Score and FRAX: How Fracture Risk Is Calculated.

Treatment of Osteoporosis

Treatment of osteoporosis pursues two main goals: slowing or halting further bone loss, and reducing fracture risk.

Lifestyle Measures

Lifestyle intervention should be foundational for everyone diagnosed with osteoporosis. These measures include:

Adequate calcium intake, through diet or supplementation, with a target of 1000 to 1200 mg daily depending on age and sex. Good sources include dairy products, leafy greens, fortified plant-based milks, and supplements if necessary.

Adequate vitamin D, through sun exposure, diet, or supplementation, with a target that achieves a serum 25-hydroxyvitamin D level of at least 30 ng/mL. Most people require supplementation, particularly in winter months or at higher latitudes.

Regular weight-bearing and muscle-strengthening exercise, which helps maintain bone density and reduces fall risk through improved balance and strength. Walking, resistance training, and activities that challenge balance are all beneficial.

Cessation of smoking, if applicable, and limiting alcohol use to moderate amounts.

Optimization of other health conditions, particularly thyroid disease and conditions affecting nutritional status.

Fall prevention measures, which is crucial since many fractures in osteoporosis result from falls. These measures include removing home hazards, optimizing lighting, avoiding medications that impair balance or cognition, addressing vision problems, ensuring adequate footwear, and other strategies to reduce fall risk.

For more on these strategies, see How to Prevent Osteoporosis: Lifestyle and Nutrition.

Medications

When lifestyle measures alone are insufficient, or when fracture risk is high, medications are indicated.

Bisphosphonates are the most commonly prescribed class. These medications slow bone resorption by osteoclasts, reducing bone loss. They include alendronate, risedronate, ibandronate, and zoledronic acid. They are effective at reducing fracture risk and are generally well-tolerated, though they require specific administration instructions to ensure absorption and occasional side effects can occur.

Denosumab is a monoclonal antibody that binds to RANKL, a molecule essential for osteoclast function. It is given as a subcutaneous injection twice yearly and is highly effective at reducing bone loss and fracture risk. It is particularly useful in patients who cannot tolerate or do not respond to bisphosphonates.

Hormone therapy, including estrogen and combinations of estrogen and progestin, can slow bone loss and reduce fracture risk in women in the perimenopause or early postmenopause. The decision to use hormone therapy involves weighing benefits for bone health against other health risks and benefits.

Anabolic agents, including teriparatide and abaloparatide, directly stimulate bone formation. They are particularly useful in patients with very low bone density or those who have suffered fractures despite treatment with other medications. They are given by subcutaneous injection.

Selective estrogen receptor modulators, including raloxifene, provide some of the benefits of estrogen for bone without acting as full estrogen replacement. They are useful in selected patients.

For a comprehensive review of medication options, see Best Treatments for Osteoporosis: Medications and Therapies.

Living With Osteoporosis

Osteoporosis is a chronic condition that requires consistent attention but should not dominate daily life. With appropriate treatment and lifestyle measures, fracture risk can be substantially reduced, and most people live normal, active lives.

Regular follow-up is important. Bone density should be reassessed periodically, typically every two years, to monitor response to treatment. Assessment of adherence to therapy is important, as many patients discontinue medications due to side effects, inconvenience, or lack of perceived benefit.

Even in the presence of osteoporosis, staying active, maintaining adequate nutrition, and preventing falls are the cornerstones of living well with the condition.

For more on living with osteoporosis, see .

Prevention of Osteoporosis

Osteoporosis is largely preventable. Building strong bones during youth, maintaining bone health during adult years, and slowing bone loss as aging occurs all contribute to preventing osteoporosis and fractures.

Adequate calcium and vitamin D throughout life, beginning in childhood and continuing throughout adulthood, is foundational. Regular physical activity, particularly weight-bearing and resistance exercise, supports bone health. Avoiding smoking and limiting alcohol are important. Maintaining a healthy body weight is protective.

For women, understanding the impact of menopause on bone health and considering appropriate preventive measures during and after the transition is important. For men, awareness of bone health and screening when indicated can identify osteoporosis early.

For more on prevention, see How to Prevent Osteoporosis: Lifestyle and Nutrition.

Conclusion

Osteoporosis remains one of the most consequential and underdiagnosed chronic diseases of our time. Every year, millions of osteoporotic fractures occur worldwide, many of which could have been prevented with earlier diagnosis and appropriate treatment.

Yet the tools for prevention and treatment are effective and accessible. Screening with DXA is simple and provides invaluable information. Lifestyle measures substantially reduce fracture risk. Modern medications can stop bone loss and in some cases restore it. The challenge is not a lack of effective interventions but rather the recognition that osteoporosis deserves attention before fractures occur.

For anyone diagnosed with osteoporosis, the path forward is clear: appropriate treatment, consistent lifestyle measures, and regular monitoring can substantially reduce fracture risk and allow a full, active life.

For more on osteoporosis and related conditions, see and .

About the Author

Prof. Jacob Giris

MD, DSc

View Profile

Clinical and research focus is the autonomic nervous system — how it regulates blood pressure, heart rate, and circulation, and what happens when this regulation breaks down. Patients are treated for Postural Tachycardia Syndrome (POTS), orthostatic intolerance, and related conditions, alongside ongoing research into the interactions between pain and the autonomic system.

Training in internal medicine was completed at Rambam Medical Center in Haifa, followed by an International MERCK Fellowship in clinical pharmacology at Vanderbilt University, and a DSc in pharmacology and physiology at the Technion — Israel Institute of Technology.

Current roles include Head of Internal Medicine Department F at Tel Aviv Sourasky Medical Center (Ichilov), Director of the Joseph Recanati Autonomic Dysfunction Center, and Professor of Medicine, Physiology and Pharmacology at the Tel Aviv University Faculty of Medicine. Published work includes more than 70 peer-reviewed papers with over 9,000 citations.

Senior medical advisor to Lema'anchem on a volunteer basis, helping patients navigate complex diagnoses and access world-class medical expertise.

Editorial Note

This article was reviewed and formatted by the MED.COM editorial process to align with international clinical standards.

Medical Disclaimer

This content is provided for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare professional regarding any medical condition.